MSF Field Research > 1 Published Research and Commentary > Leishmaniasis/Kala Azar > Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

Please use this identifier to cite or link to this item: http://hdl.handle.net/10144/246593
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!


Download this article:
View/Open File Description Size Format
Thumbnail
View/Open
1110_Sinha_Liposomal-amphotericin-B-for-visceral-leishmaniasis-in-human-immunodeficiency-virus-co-infected-patients_Clinical-Infectious-Diseases-53-7-e91-e98.pdfMain article165KbAdobe PDF

Title: Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India
Authors: Sinha, Prabhat K
van Griensven, Johan
Pandey, Krishna
Kumar, Nawin
Verma, Neena
Mahajan, Raman
Kumar, Pankaj
Kumar, Ranjeet
Das, Pradeeb
Mitra, Gaurab
Flevaud, Laurence
Ferreyra, Cecilia
Remartinez, Daniel
Pece, Manuel
Palma, Pedro Pablo
Affiliation: Rajendra Memorial Research Institute of Medical Science, Patna, Bihar; Medecins Sans Frontieres–India, Operational Center Barcelona–Athens, New Delhi, India; Institute of Tropical Medicine, Antwerp, Belgium; Medecins Sans Frontieres, Medical Department, Operational Center Barcelona– Athens, Barcelona, Spain
Citation: Clin Infect Dis 2011; 53(7):e91-e98
Publisher: Oxford University Press
Journal: Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America
Issue Date: Oct-2011
URI: http://hdl.handle.net/10144/246593
DOI: 10.1093/cid/cir521
PubMed ID: 21890763
Additional Links: http://cid.oxfordjournals.org/content/53/7/e91.abstract
Abstract: Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of liposomal amphotericin B in VL-HIV coinfection. We report the 2-year treatment outcomes of VL-HIV-coinfected patients treated with liposomal amphotericin B followed by combination antiretroviral treatment (cART) in Bihar, India.
Type: Article
Language: en
MeSH: Adolescent
Adult
Amphotericin B
Anti-HIV Agents
Antifungal Agents
Antiretroviral Therapy, Highly Active
Female
HIV Infections
Humans
India
Leishmaniasis, Visceral
Male
Recurrence
Survival Analysis
Treatment Failure
Treatment Outcome
ISSN: 1537-6591
Rights: Archived with thanks to Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Appears in topics: Leishmaniasis/Kala Azar

Related articles on PubMed
bullet
bullet
bullet
Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
Salih NA, van Griensven J, Chappuis F, Antierens A, Mumina A, Hammam O, Boulle P, Alirol E, Alnour M, Elhag MS, Manzi M, Kizito W, Zachariah R
2014 Feb
bullet
bullet
Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A
2007 Oct
See all 180 articles

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.

 

OR Logo Powered by Open Repository | Cookies

My MSF

MSF logo MSF Field Research

Apr 19, 2014